Table 5.

Comparison between clinical and US assessments in the 3 patient populations for both patients and entheses.

VariablesSensitivitySpecificityPPVNPVCohen κ
PsA
  Per patient0.91 (0.86–0.97)0.06 (0.00–0.13)0.66 (0.58–0.74)0.27 (0.01–0.54)−0.03 (−0.14 to 0.08)
  Per enthesis0.60 (0.53–0.66)0.48 (0.44–0.52)0.28 (0.24–0.33)0.78 (0.74–0–82)0.06 (0.00–0.12)
Psoriasis
  Per patient0.93 (0.84–1.00)0.10 (0.00–0.22)0.60 (0.46–0.74)0.50 (0.01–0.99)0.03 (−0.14 to 0.21)
  Per enthesis0.43 (0.30–0.56)0.59 (0.53–0.65)0.20 (0.13–0.27)0.82 (0.76–0.87)0.02 (−0.08 to 0.11)
FMS
  Per patient0.74 (0.62–0.87)0.25 (0.00–0.67)0.92 (0.84–1.00)0.08 (0.00–0.22)−0.00 (−0.22 to 0.22)
  Per enthesis0.25 (0.17–0.32)0.71 (0.64–0.77)0.36 (0.25–0.46)0.59 (0.52–0.65)−0.05 (−0.16 to 0.06)
  • The findings are reported as mean values (lower–upper limit) of all of the entheses assessed both clinically and by US. Data were computed considering clinical assessment as the gold standard. FMS: fibromyalgia syndrome; NPV: negative predictive value; PPV: positive predictive value; PsA: psoriatic arthritis; US: ultrasonography.